|
Infectious diseases
Adverse drug reactions following treatment of latent tuberculosis infection: a linked national tuberculosis surveillance with claims database
Yu-Seon Jung, Sun-Young Jung, Jae-Eun Lee, Kyungeun Lee, Jae Chol Choi
Korean J Intern Med. 2024;39(6):979-988. Published online October 22, 2024
Background/Aims: Few real-world studies explored factors associated with latent tuberculosis infection (LTBI) treatment-related adverse drug reactions (ADRs). This study evaluate ADRs that lead to the discontinuation of LTBI treatment and identify the associated factors, including age groups and dru..
|
|
|
2024 KSoLA consensus on secondary dyslipidemia
Hoyoun Won, Jae Hyun Bae, Hyunjung Lim, Minji Kang, Minjoo Kim, Sang-Hak Lee; on behalf of the Clinical Practice Guidelines Committee, Korean Society of Lipid and Atherosclerosis (KSoLA)
Korean J Intern Med. 2024;39(5):717-730. Published online August 30, 2024
Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes of hypercholesterolemia and hypertriglyceridemia include an u..
|
|
|
Pulmonology
Clinical characteristics of patients with COVID-19 vaccine-related pneumonitis: a case series and literature review
Ji Young Park, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Hwan Il Kim, Seung Hun Jang, Ki-Suck Jung, Yong Kyun Kim, Hyun Ah Kim, In Jae Lee
Korean J Intern Med. 2022;37(5):989-1001. Published online August 22, 2022
Background/Aims: Pulmonary toxicities of coronavirus disease 2019 (COVID-19) vaccination are exceedingly rare. However, there are a few reported cases after mRNA vaccination, especially from Asian countries. The purpose of this study was to report the clinical characteristics of patients with COVID-..
|
|
|
Infectious diseases
Can reactogenicity predict immunogenicity after COVID-19 vaccination?
Young Hoon Hwang, Kyoung-Ho Song, Yunsang Choi, Suryeong Go, Su-Jin Choi, Jongtak Jung, Chang Kyung Kang, Pyoeng Gyun Choe, Nam-Joong Kim, Wan Beom Park, Myoung-don Oh
Korean J Intern Med. 2021;36(6):1486-1491. Published online May 28, 2021
Background/Aims: This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination.
Methods: Adverse events were prospectively evaluated using an electronic diary in 135 heal..
|
|
|
Hemato-oncology
Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience
Min-Young Lee, Seug Yun Yoon, Kyoung Ha Kim, Namsu Lee, Ha Youn Kim, Jung Hwa Hwang, Jong-Ho Won
Korean J Intern Med. 2021;36(3):689-698. Published online January 8, 2021
Background/Aims: A better understanding of cancer cell biology has led to the discovery and development of several new targeted agents for cancer. These drugs are widely used in cancer treatment and have good toxicity profiles. However, some patients are extremely sensitive to these drugs and can de..
|
|
|
Pulmonology
Cutaneous adverse drug reactions in patients with peripheral blood eosinophilia during antituberculosis treatment
Tae-Ok Kim, Hong-Joon Shin, Yu-Il Kim, Sung-Chul Lim, Young-Il Koh, Yong-Soo Kwon
Korean J Intern Med. 2019;34(5):1050-1057. Published online March 19, 2019
Background/Aims: Peripheral eosinophilia during tuberculosis (TB) treatment is common, but has not been fully evaluated. The aim of this study was to determine the prevalence and clinical significance of peripheral blood eosinophilia in patients undergoing anti-TB treatment.
Methods: We retrospecti..
|
|
|
Cardiology
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational
cohort study
Seng Chan You, Hojun Park, Dukyong Yoon, Sooyoung Park, Boyoung Joung, Rae Woong Park
Korean J Intern Med. 2019;34(1):90-98. Published online November 27, 2017
Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of ent..
|
|
|
Gastroenterology
Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B
Chang Wook Kim, Chang Seop Kim, Hee Yeon Kim, Chang Don Lee, Kyungha Yu, Cyril Llamoso, Heon Ju Lee
Korean J Intern Med. 2018;33(1):91-101. Published online December 13, 2017
Background/Aims: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation in patient’s number. A large-scale nation-wide real-world surveillance study was carried..
|
|
|
